{"organizations": [], "uuid": "623ad4e0cad33875031255cb84533337e2fa0bc7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets", "section_title": "Markets &amp; Finance News | Reuters.com", "url": "https://www.reuters.com/article/brief-medicinova-posts-results-of-phase/brief-medicinova-posts-results-of-phase-2-clinical-trial-of-mn-166-in-methamphetamine-dependence-idUSASC09U5J", "country": "US", "domain_rank": 408, "title": "BRIEF-MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.983, "site_type": "news", "published": "2018-03-29T19:56:00.000+03:00", "replies_count": 0, "uuid": "623ad4e0cad33875031255cb84533337e2fa0bc7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-medicinova-posts-results-of-phase/brief-medicinova-posts-results-of-phase-2-clinical-trial-of-mn-166-in-methamphetamine-dependence-idUSASC09U5J", "ord_in_thread": 0, "title": "BRIEF-MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "medicinova inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - MediciNova Inc:\n* MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE\n* MEDICINOVA INC - ‍DID NOT MEET PRIMARY ENDPOINT OF METHAMPHETAMINE ABSTINENCE CONFIRMED VIA URINE DRUG SCREENS DURING FINAL TWO WEEKS OF TREATMENT​\n* MEDICINOVA INC - ‍MN-166 (IBUDILAST) DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE​\n* MEDICINOVA INC - ‍THERE WAS NOT AN INCREASED RATE OF SERIOUS OR SEVERE ADVERSE EVENTS IN MN-166 (IBUDILAST) GROUP COMPARED TO PLACEBO GROUP​\n* MEDICINOVA INC SAYS THERE WERE NO INFECTIONS, NO CANCERS, NO CARDIOVASCULAR EVENTS NO DEATHS RELATED TO MN-166\n* MEDICINOVA - COMMON TREATMENT-RELATED ADVERSE EVENTS DURING STUDY WERE GASTROINTESTINAL ADVERSE EVENTS, OCCURRED WITH HIGHER FREQUENCY IN MN-166 GROUP​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T19:56:00.000+03:00", "crawled": "2018-03-29T15:02:48.107+03:00", "highlightTitle": ""}